Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah A Spinler

Showing results (11-20 of 78) with videos related to

Pageof 8
Sort By:
The Annals of Pharmacotherapy|September 29, 2011
The role of apixaban for venous and arterial thromboembolic diseaseRathasen Prom, Sarah A Spinler
Journal of Managed Care Pharmacy : JMCP|June 6, 2009
Review of prasugrel for the secondary prevention of atherothrombosisSarah A Spinler, Catherine Rees
The Annals of Pharmacotherapy|May 15, 2008
Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous?A Janelle Hermosillo, Sarah A Spinler
The Annals of Pharmacotherapy|October 26, 2002
Early statin therapy for acute coronary syndromesSimon De Denus, Sarah A Spinler
The Annals of Pharmacotherapy|August 19, 2003
Decreased argatroban clearance unaffected by hemodialysis in anasarcaSimon de Denus, Sarah A Spinler
Pharmacotherapy|October 30, 2008
Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseasesBrooke E Baetz, Sarah A Spinler
Pharmacotherapy|January 17, 2002
Conversion of recent-onset atrial fibrillation with intravenous amiodarone: a meta-analysis of randomized controlled trialsDaniel E Hilleman, Sarah A Spinler
Trends in Cardiovascular Medicine|December 18, 2020
COVID-19 and thrombosis: From bench to bedsideMohammad A M Ali, Sarah A Spinler
Pharmacotherapy|February 13, 2013
Rash associated with dabigatran etexilateKim To, Carl Reynolds, Sarah A Spinler
Clinical Therapeutics|January 19, 2013
Rivaroxaban: an oral factor Xa inhibitorTyan F Thomas, Valerie Ganetsky, Sarah A Spinler
Pageof 8

Showing results (11-20 of 78) with videos related to

Sort By:
Pageof 8
The Annals of Pharmacotherapy|September 29, 2011
The role of apixaban for venous and arterial thromboembolic diseaseRathasen Prom, Sarah A Spinler
Journal of Managed Care Pharmacy : JMCP|June 6, 2009
Review of prasugrel for the secondary prevention of atherothrombosisSarah A Spinler, Catherine Rees
The Annals of Pharmacotherapy|May 15, 2008
Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous?A Janelle Hermosillo, Sarah A Spinler
The Annals of Pharmacotherapy|October 26, 2002
Early statin therapy for acute coronary syndromesSimon De Denus, Sarah A Spinler
The Annals of Pharmacotherapy|August 19, 2003
Decreased argatroban clearance unaffected by hemodialysis in anasarcaSimon de Denus, Sarah A Spinler
Pharmacotherapy|October 30, 2008
Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseasesBrooke E Baetz, Sarah A Spinler
Pharmacotherapy|January 17, 2002
Conversion of recent-onset atrial fibrillation with intravenous amiodarone: a meta-analysis of randomized controlled trialsDaniel E Hilleman, Sarah A Spinler
Trends in Cardiovascular Medicine|December 18, 2020
COVID-19 and thrombosis: From bench to bedsideMohammad A M Ali, Sarah A Spinler
Pharmacotherapy|February 13, 2013
Rash associated with dabigatran etexilateKim To, Carl Reynolds, Sarah A Spinler
Clinical Therapeutics|January 19, 2013
Rivaroxaban: an oral factor Xa inhibitorTyan F Thomas, Valerie Ganetsky, Sarah A Spinler
Pageof 8